BioXcel Therapeutics announces pricing of $7M public offering
seekingalpha
22 Nov 2024
BioXcel Therapeutics (NASDAQ:BTAI) on Friday announced the pricing of an underwritten public offering of 5.6M shares of its common stock and accompanying warrants to purchase up to 5.6M shares of common stock and pre-funded warrants to purchase up to 9M shares of common stock andon- accompanying warrants to purchase up to 9M shares, at a combined public offering price of $0.48 per share and accompanying warrant.
BTAI -7.53% premarket to $0.5276.
Gross proceeds to the company from the offering are expected to be about $7 million.
Each of the accompanying warrants will have an exercise price of $0.48 per underlying share of common stock.
The offering is expected to close on or about November 25.
Source: Press Release
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.